Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism

Diana L. Ross, William M. Klykylo, Robert Hitzemann

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Fenfluramine therapy has been reported to improve behavior in infantile autism and has been associated with a decrease in abnormally increased blood serotonin content. The primary central effect has not been proved to be serotonergic. Beta-endorphin is involved in the anorexic effect of fenfluramine and may play a role in autism. Nine children with infantile autism were treated with fenfluramine in double-blind, placebocrossover design. Transient anorexia was the only adverse effect. Autistic behavior was reported to improve in three patients, but objective psychometric tests were unchanged. Beta-endorphin-like immunoreactivity was determined in lumbar cerebrospinal fluid of patients during and before or after treatment with fenfluramine and then was compared to normal controls. Beta-endorphin was elevated significantly in the baseline autistic group (p <.005) and was reduced toward control values during fenfluramine treatment. The results are consistent with a role for beta-endorphin in infantile autism and in the mechanism of fenfluramine treatment.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalPediatric Neurology
Volume3
Issue number2
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Fenfluramine
beta-Endorphin
Autistic Disorder
Anorexia
Therapeutics
Psychometrics
Cerebrospinal Fluid
Serotonin

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. / Ross, Diana L.; Klykylo, William M.; Hitzemann, Robert.

In: Pediatric Neurology, Vol. 3, No. 2, 1987, p. 83-86.

Research output: Contribution to journalArticle

Ross, Diana L. ; Klykylo, William M. ; Hitzemann, Robert. / Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. In: Pediatric Neurology. 1987 ; Vol. 3, No. 2. pp. 83-86.
@article{6ea090a138e94410bbb22ad0b6b35990,
title = "Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism",
abstract = "Fenfluramine therapy has been reported to improve behavior in infantile autism and has been associated with a decrease in abnormally increased blood serotonin content. The primary central effect has not been proved to be serotonergic. Beta-endorphin is involved in the anorexic effect of fenfluramine and may play a role in autism. Nine children with infantile autism were treated with fenfluramine in double-blind, placebocrossover design. Transient anorexia was the only adverse effect. Autistic behavior was reported to improve in three patients, but objective psychometric tests were unchanged. Beta-endorphin-like immunoreactivity was determined in lumbar cerebrospinal fluid of patients during and before or after treatment with fenfluramine and then was compared to normal controls. Beta-endorphin was elevated significantly in the baseline autistic group (p <.005) and was reduced toward control values during fenfluramine treatment. The results are consistent with a role for beta-endorphin in infantile autism and in the mechanism of fenfluramine treatment.",
author = "Ross, {Diana L.} and Klykylo, {William M.} and Robert Hitzemann",
year = "1987",
doi = "10.1016/0887-8994(87)90032-4",
language = "English (US)",
volume = "3",
pages = "83--86",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism

AU - Ross, Diana L.

AU - Klykylo, William M.

AU - Hitzemann, Robert

PY - 1987

Y1 - 1987

N2 - Fenfluramine therapy has been reported to improve behavior in infantile autism and has been associated with a decrease in abnormally increased blood serotonin content. The primary central effect has not been proved to be serotonergic. Beta-endorphin is involved in the anorexic effect of fenfluramine and may play a role in autism. Nine children with infantile autism were treated with fenfluramine in double-blind, placebocrossover design. Transient anorexia was the only adverse effect. Autistic behavior was reported to improve in three patients, but objective psychometric tests were unchanged. Beta-endorphin-like immunoreactivity was determined in lumbar cerebrospinal fluid of patients during and before or after treatment with fenfluramine and then was compared to normal controls. Beta-endorphin was elevated significantly in the baseline autistic group (p <.005) and was reduced toward control values during fenfluramine treatment. The results are consistent with a role for beta-endorphin in infantile autism and in the mechanism of fenfluramine treatment.

AB - Fenfluramine therapy has been reported to improve behavior in infantile autism and has been associated with a decrease in abnormally increased blood serotonin content. The primary central effect has not been proved to be serotonergic. Beta-endorphin is involved in the anorexic effect of fenfluramine and may play a role in autism. Nine children with infantile autism were treated with fenfluramine in double-blind, placebocrossover design. Transient anorexia was the only adverse effect. Autistic behavior was reported to improve in three patients, but objective psychometric tests were unchanged. Beta-endorphin-like immunoreactivity was determined in lumbar cerebrospinal fluid of patients during and before or after treatment with fenfluramine and then was compared to normal controls. Beta-endorphin was elevated significantly in the baseline autistic group (p <.005) and was reduced toward control values during fenfluramine treatment. The results are consistent with a role for beta-endorphin in infantile autism and in the mechanism of fenfluramine treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023267814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023267814&partnerID=8YFLogxK

U2 - 10.1016/0887-8994(87)90032-4

DO - 10.1016/0887-8994(87)90032-4

M3 - Article

C2 - 2977280

AN - SCOPUS:0023267814

VL - 3

SP - 83

EP - 86

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 2

ER -